Insider Selling: Inogen (NASDAQ:INGN) EVP Sells $72,190.80 in Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,938 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at $33,257.40. This represents a 68.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Inogen Stock Performance

Shares of INGN stock traded up $0.07 during trading on Monday, hitting $6.67. 157,740 shares of the company were exchanged, compared to its average volume of 304,270. The firm has a market capitalization of $180.62 million, a price-to-earnings ratio of -7.33 and a beta of 1.58. The business’s 50-day simple moving average is $6.60 and its 200 day simple moving average is $6.42. Inogen, Inc has a twelve month low of $5.34 and a twelve month high of $9.13.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The company had revenue of $85.11 million during the quarter, compared to analyst estimates of $82.35 million. Inogen had a negative net margin of 7.08% and a negative return on equity of 12.90%. On average, equities analysts forecast that Inogen, Inc will post -0.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inogen

Several large investors have recently bought and sold shares of INGN. CSM Advisors LLC bought a new stake in shares of Inogen in the third quarter valued at about $2,973,000. Armistice Capital LLC raised its stake in shares of Inogen by 46.3% in the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock valued at $8,494,000 after purchasing an additional 400,000 shares in the last quarter. Quantinno Capital Management LP lifted its position in Inogen by 78.1% in the first quarter. Quantinno Capital Management LP now owns 90,995 shares of the medical technology company’s stock worth $562,000 after purchasing an additional 39,915 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Inogen by 203.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock worth $3,622,000 after purchasing an additional 393,310 shares during the period. Finally, Hsbc Holdings PLC boosted its stake in Inogen by 75.4% during the fourth quarter. Hsbc Holdings PLC now owns 60,482 shares of the medical technology company’s stock worth $406,000 after buying an additional 25,998 shares in the last quarter. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a research note on Friday, May 8th. Freedom Capital upgraded Inogen to a “strong-buy” rating in a report on Tuesday, April 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.